14-6-7　ⓔ文献

  1. 溶血性尿毒症症候群の診断・治療ガイドライン．http://www.jspn.jp/file/pdf/20140618_guideline.pdf

  2. 香美祥二：非典型溶血性尿毒症症候群 (aHUS) 診療ガイド2015. 日本腎臓学会雑誌, 2016; 58: 62–75. http://www.jsn.or.jp/guideline/ahus-2016.php

  3. 伊藤秀一：HUS up to date　欧州における大規模集団感染を中心に．日本小児腎不全学会雑誌, 2013; 33: 16–19.

  4. Mayer CL, Leibowitz CS, et al: Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel), 2012; 4: 1261–1287.

  5. Lee MS, Tesh VL: Roles of Shiga toxins in immunopathology. Toxins (Basel), 2019; 11: pii: E212.

  6. Exeni RA, Fernandez–Brando RJ, et al: Pathogenic role of inflammatory response during Shiga toxin–associated hemolytic uremic syndrome (HUS). Pediatr Nephrol, 2018; 33: 2057–2071.

  7. Fremeaux–Bacchi V, Fakhouri F, et al: Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol, 2013; 8: 554–562.

  8. Ardissino G, Tel F, et al: ItalKid–HUS Network. A simple prognostic index for Shigatoxin–related hemolytic uremic syndrome at onset: data from the ItalKid–HUS network. Eur J Pediatr, 2018; 177: 1667–1674.

  9. Keenswijk W, Vanmassenhove J, et al: Blood urea nitrogen to serum creatinine ratio is an accurate predictor of outcome in diarrhea–associated hemolytic uremic syndrome, a preliminary study. Eur J Pediatr, 2017; 176: 355–360.

  10. Hickey CA, Beattie TJ, et al: Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med, 2011; 165: 884–889.

  11. Ardissino G, Tel F, et al: Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics, 2016; 137:e20152153.

  12. Takanashi J, Taneichi H, et al: Clinical and radiologic features of encephalopathy during 2011 E coli O111 outbreak in Japan. Neurology, 2014; 82: 564–572.

  13. Legendre CM, Licht C, et al: Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med, 2013; 368: 2169–2181.

  14. Ito N, Hataya H, et al: Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol, 2016; 20: 265–272.